FOR IMMEDIATE RELEASE
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
19 March 2020
OKYO Pharma Limited
(“OKYO” or the “Company”)
Placing to raise £560,000
OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it has conditionally placed 112,000,000 new ordinary shares of no par value in the Company (the “Placing Shares”) at a placing price of 0.5 pence each (the “Placing Price”) to raise £560,000 (before expenses) (the “Placing”). The Placing Shares will be issued with warrants attached on a one-for-one basis, exercisable at a price of 0.55 pence for a period of five years from today’s date.
The Placing Shares were placed privately with Panetta Partners Ltd, a major shareholder in the Company and a further strategic investor. The Placing utilises substantially all of the Company’s existing headroom to issue shares on a non pre-emptive basis, which was taken at the annual general meeting of the Company held on 2 March 2020. The Placing Shares, when issued will represent 19.98% of the Company’s existing share capital and 16.65% of the enlarged share capital. No prospectus will be published in connection with the Placing.
The Placing Price represents a discount of 60% to the mid-market closing price of the Company’s ordinary shares on 18 March 2020. However the Directors were mindful in agreeing the Placing Price that markets are currently experiencing exceptional levels of volatility not seen in recent years, and felt it appropriate to proceed at the Placing Price to secure additional cash resources to allow the further development of the Company’s lead product candidates and to be in a position of financial security until markets return to normal operation.
OKYO intends to use the net proceeds received from this Placing (i) to complete IND enabling studies of Chemerin for dry eye followed by IND submission by Q1 2021, (ii) to complete Pre-IND studies and validation of Proof of Concept for Bam-8 for the treatment of ocular and chronic pain, and (iii) for working capital and other general expenses.
OKYO Chairman Willy Simon commented:
“I am very pleased to announce this placing that results in the business being better capitalised as we endure a period of huge disruption on the financial markets. This additional funding will allow us to make substantial progress in our clinical programmes and I look forward to sharing the results with shareholders in due course”.
Completion of the Placing
Completion of the Placing is conditional upon the Placing Shares being admitted to listing on the Official List (standard listing segment) and to trading on the London Stock Exchange’s main market for listed securities (“Admission“) on or before 31 March 2020.
Admission, Settlement and Dealings in Placing Shares
Applications will be made to the FCA and to the London Stock Exchange for Admission in respect of all the Placing Shares proposed to be issued on completion of the Placing. It is expected that Admission will become effective, and that dealings in the Placing Shares are expected to commence, at 8.00 a.m. on 24 March 2020.
The rights attaching to the Placing Shares will be uniform in all respects and all of the Placing Shares will rank pari passu, and form a single class for all purposes with, the existing issued shares of no par value in the Company.
Following Admission of the Placing Shares, the enlarged Share Capital will be 672,471,919 ordinary shares of no par value and 30.18% of the ordinary shares will be in public hands.
The person who arranged for the release of this announcement on behalf of the Company was Tiziano Lazzaretti, Chief Financial Officer of OKYO.
OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
|OKYO Pharma Limited||Willy Simon||+44 (0)20 7382 8300|
|Shore Capital Limited (Broker)||Antonio Bossi|
|+44 (0)20 7601 6100|
For further information, please visit the Company’s website at www.okyopharma.com.